MXPA03010403A - Derivados de dipeptido que tienen un grupo 2-tioacilo n-terminal como inhibidores de vasopeptidasa. - Google Patents
Derivados de dipeptido que tienen un grupo 2-tioacilo n-terminal como inhibidores de vasopeptidasa.Info
- Publication number
- MXPA03010403A MXPA03010403A MXPA03010403A MXPA03010403A MXPA03010403A MX PA03010403 A MXPA03010403 A MX PA03010403A MX PA03010403 A MXPA03010403 A MX PA03010403A MX PA03010403 A MXPA03010403 A MX PA03010403A MX PA03010403 A MXPA03010403 A MX PA03010403A
- Authority
- MX
- Mexico
- Prior art keywords
- terminal
- dipeptide derivatives
- thioacyl group
- vasopeptidase inhibitors
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 108010016626 Dipeptides Proteins 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 abstract 1
- 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 abstract 1
- 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000003729 Neprilysin Human genes 0.000 abstract 1
- 108090000028 Neprilysin Proteins 0.000 abstract 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 abstract 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- -1 methoxyacetyl Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29108801P | 2001-05-15 | 2001-05-15 | |
| US33957501P | 2001-12-11 | 2001-12-11 | |
| PCT/EP2002/005293 WO2002092622A2 (en) | 2001-05-15 | 2002-05-14 | Dipeptide derivatives having a n-terminal 2-thioacyl group as vasopeptidase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03010403A true MXPA03010403A (es) | 2004-03-09 |
Family
ID=26966569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03010403A MXPA03010403A (es) | 2001-05-15 | 2002-05-14 | Derivados de dipeptido que tienen un grupo 2-tioacilo n-terminal como inhibidores de vasopeptidasa. |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US6777443B2 (enExample) |
| EP (2) | EP1392720A2 (enExample) |
| JP (1) | JP4390458B2 (enExample) |
| KR (1) | KR100908152B1 (enExample) |
| CN (1) | CN1649893A (enExample) |
| AR (1) | AR035890A1 (enExample) |
| AU (1) | AU2002314067B2 (enExample) |
| BR (1) | BR0209652A (enExample) |
| CA (1) | CA2449292A1 (enExample) |
| CO (1) | CO5540347A2 (enExample) |
| CZ (1) | CZ20033077A3 (enExample) |
| HU (1) | HUP0304084A3 (enExample) |
| IL (1) | IL158772A0 (enExample) |
| MX (1) | MXPA03010403A (enExample) |
| MY (1) | MY127495A (enExample) |
| NO (1) | NO20035084L (enExample) |
| NZ (1) | NZ529438A (enExample) |
| PE (1) | PE20030042A1 (enExample) |
| PL (1) | PL366786A1 (enExample) |
| RU (1) | RU2298559C2 (enExample) |
| SK (1) | SK14032003A3 (enExample) |
| TW (1) | TWI295996B (enExample) |
| WO (1) | WO2002092622A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6777443B2 (en) * | 2001-05-15 | 2004-08-17 | Novartis Ag | Dipeptide derivatives |
| WO2003004456A1 (en) * | 2001-07-06 | 2003-01-16 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives |
| WO2003027091A1 (en) * | 2001-09-21 | 2003-04-03 | Novartis Ag | Pyrane derivatives as both ace- and nep- inhibitors |
| DE60315795T2 (de) * | 2002-01-17 | 2008-06-05 | Novartis Ag | Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren |
| US7468390B2 (en) | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
| ATE409476T1 (de) * | 2002-06-13 | 2008-10-15 | Novartis Pharma Gmbh | Calciumsalze von statinen aus indol |
| ATE493973T1 (de) | 2004-06-04 | 2011-01-15 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
| CA2590278A1 (en) * | 2004-12-15 | 2006-06-22 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors |
| WO2006097570A1 (en) * | 2005-03-14 | 2006-09-21 | Orion Corporation | A combination treatment for enhancing diuresis |
| US7390789B2 (en) * | 2005-09-13 | 2008-06-24 | William H Simmons | Thio-containing inhibitors of aminopeptidase P, and compositions thereof |
| US7400236B2 (en) | 2005-10-21 | 2008-07-15 | Gm Global Technology Operations, Inc. | Vehicular lane monitoring system utilizing front and rear cameras |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| US20120157387A1 (en) * | 2006-11-28 | 2012-06-21 | Apotex Technologies Inc. | Orally bioavailable d-gamma-glutamyl-d-tryptophan |
| TW200838501A (en) * | 2007-02-02 | 2008-10-01 | Theravance Inc | Dual-acting antihypertensive agents |
| TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
| TWI406850B (zh) | 2007-06-05 | 2013-09-01 | Theravance Inc | 雙效苯并咪唑抗高血壓劑 |
| WO2009035543A1 (en) | 2007-09-07 | 2009-03-19 | Theravance, Inc. | Dual-acting antihypertensive agents |
| EP2225210B1 (en) | 2007-12-11 | 2012-04-25 | Theravance, Inc. | Dual-acting benzoimidazole derivative and their use as antihypertensive agents |
| EP2297113A1 (en) | 2008-04-29 | 2011-03-23 | Theravance, Inc. | Dual-acting antihypertensive agents |
| WO2010011821A2 (en) | 2008-07-24 | 2010-01-28 | Theravance, Inc. | Dual-acting antihypertensive agents |
| JP5833000B2 (ja) | 2009-07-07 | 2015-12-16 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | 二重に作用するピラゾール抗高血圧症薬 |
| WO2011011232A1 (en) | 2009-07-22 | 2011-01-27 | Theravance, Inc. | Dual-acting oxazole antihypertensive agents |
| EP2526095A1 (en) * | 2010-01-19 | 2012-11-28 | Theravance, Inc. | Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents |
| EA201391421A1 (ru) * | 2011-03-31 | 2014-02-28 | Апотекс Текнолоджиз Инк. | Пролекарства d-гамма-глутамил-d-триптофана и d-гамма-глутамил-l-триптофана |
| US9212206B1 (en) * | 2014-11-24 | 2015-12-15 | William H Simmons | 4-Fluoro-Thio-containing inhibitors of APP2, compositions thereof and method of use |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| US11396497B2 (en) | 2018-05-04 | 2022-07-26 | New Mexico Tech University Research Park Corporation | Proteasome inhibitors |
| CN113956183B (zh) * | 2021-10-28 | 2023-06-20 | 成都市科隆化学品有限公司 | 一种Boc-Ser(Bzl)-OH及其制备方法 |
| CN121039147A (zh) * | 2023-05-05 | 2025-11-28 | 上海济煜医药科技股份有限公司 | 一种短肽类化合物及其制备方法和医药应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3432307A1 (de) * | 1984-09-03 | 1986-04-10 | Boehringer Ingelheim KG, 6507 Ingelheim | Aminosaeurederivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen |
| ES2074257T3 (es) | 1989-11-27 | 1995-09-01 | Santen Pharmaceutical Co Ltd | Derivados de aminoacidos. |
| FR2679564A1 (fr) | 1991-07-23 | 1993-01-29 | Inst Nat Sante Rech Med | Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent. |
| ATE159515T1 (de) | 1992-07-21 | 1997-11-15 | Ciba Geigy Ag | Oxamidsäure-derivate als hypocholesterämische mittel |
| US5432186A (en) * | 1993-11-16 | 1995-07-11 | Ciba-Geigy Corporation | Cyclic amino acid derivatives |
| US5508266A (en) | 1994-06-22 | 1996-04-16 | Ciba-Geigy Corporation | Gem-disubstituted amino acid derivatives |
| AU5122196A (en) | 1995-03-31 | 1996-10-16 | Takeda Chemical Industries Ltd. | Cysteine protease inhibitor |
| US6147114A (en) * | 1995-04-25 | 2000-11-14 | Fuji Yakuhin Kogyo Kabushiki Kaisha | Highly water-soluble metalloproteinase inhibitors |
| DE69627483T2 (de) | 1995-05-10 | 2004-04-01 | Darwin Discovery Ltd., Slough | Peptidartige stoffe, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung |
| JPH11507352A (ja) * | 1995-06-07 | 1999-06-29 | ジンタ・インコーポレイテッド | 新規カルバメート基本カチオン性脂質 |
| US6245809B1 (en) * | 1996-12-09 | 2001-06-12 | Cor Therapeutics Inc. | Integrin antagonists |
| US6492421B1 (en) * | 1997-07-31 | 2002-12-10 | Athena Neurosciences, Inc. | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| DE19745151A1 (de) | 1997-10-14 | 1999-04-15 | Basf Ag | Neue Verbindungen zur Behandlung von Krankheiten, die mit der biologischen Wirkung von Endothelin assoziiert sind |
| FR2770844A1 (fr) | 1997-11-10 | 1999-05-14 | Inst Nat Sante Rech Med | Inhibiteurs de toxines clostridiales et compositions pharmaceutiques les contenant |
| US6576766B1 (en) * | 1997-11-12 | 2003-06-10 | Ariad Pharmaceuticals, Inc. | Signal transduction inhibitors, compositions containing them |
| AU750048B2 (en) | 1998-04-23 | 2002-07-11 | Novartis Ag | Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme |
| ID26822A (id) | 1998-04-23 | 2001-02-15 | Novartis Ag | Inhibitor tiol tertentu dari enzim pengubah endotelin |
| EP1140984B1 (en) | 1998-12-31 | 2003-02-12 | Aventis Pharmaceuticals Inc. | Selective inhibitors of mmp-12 |
| FR2788526B1 (fr) | 1999-01-20 | 2002-07-05 | Inst Nat Sante Rech Med | Composes tripeptidiques utiles a titre d'hinhibiteurs selectifs de l'aminopeptidase a et compositions pharmaceutiques correspondantes |
| CO5160290A1 (es) | 1999-03-29 | 2002-05-30 | Novartis Ag | Derivados de acido fenoxifeniloxamico sustituido . |
| US6503949B1 (en) * | 1999-05-17 | 2003-01-07 | Noro Nordisk A/S | Glucagon antagonists/inverse agonists |
| GB9917909D0 (en) * | 1999-07-31 | 1999-09-29 | Synphar Lab Inc | Cysteine protease inhibitors |
| CA2383002A1 (en) * | 1999-08-27 | 2001-03-08 | Cytovia, Inc. | Substituted .alpha.-hydroxy acid caspase inhibitors and the use thereof |
| US6803383B2 (en) * | 2000-03-27 | 2004-10-12 | The Scripps Research Institute | Inhibition of angiogenesis and tumor growth |
| AU2001287289A1 (en) | 2000-04-03 | 2001-10-15 | Bristol-Myers Squibb Company | Vasopeptidase inhibitors to treat isolated systolic hypertensions |
| HUP0301335A3 (en) | 2000-04-12 | 2006-02-28 | Novartis Ag | Combination of organic compounds |
| US20020013307A1 (en) | 2000-05-23 | 2002-01-31 | Pablo Lapuerta | Use of vasopeptidase inhibitors to treat or slow the progression of cognitive dysfunction and to treat and/or prevent dementia |
| US6777443B2 (en) * | 2001-05-15 | 2004-08-17 | Novartis Ag | Dipeptide derivatives |
-
2002
- 2002-05-09 US US10/142,693 patent/US6777443B2/en not_active Expired - Fee Related
- 2002-05-13 AR ARP020101736A patent/AR035890A1/es unknown
- 2002-05-14 IL IL15877202A patent/IL158772A0/xx unknown
- 2002-05-14 EP EP02740600A patent/EP1392720A2/en not_active Withdrawn
- 2002-05-14 NZ NZ529438A patent/NZ529438A/en unknown
- 2002-05-14 EP EP10164769A patent/EP2239268A1/en not_active Withdrawn
- 2002-05-14 CA CA002449292A patent/CA2449292A1/en not_active Abandoned
- 2002-05-14 JP JP2002589505A patent/JP4390458B2/ja not_active Expired - Fee Related
- 2002-05-14 CZ CZ20033077A patent/CZ20033077A3/cs unknown
- 2002-05-14 WO PCT/EP2002/005293 patent/WO2002092622A2/en not_active Ceased
- 2002-05-14 SK SK1403-2003A patent/SK14032003A3/sk not_active Application Discontinuation
- 2002-05-14 KR KR1020037014849A patent/KR100908152B1/ko not_active Expired - Fee Related
- 2002-05-14 CN CNA028118499A patent/CN1649893A/zh active Pending
- 2002-05-14 MX MXPA03010403A patent/MXPA03010403A/es active IP Right Grant
- 2002-05-14 RU RU2003134153/04A patent/RU2298559C2/ru not_active IP Right Cessation
- 2002-05-14 MY MYPI20021740A patent/MY127495A/en unknown
- 2002-05-14 TW TW091110028A patent/TWI295996B/zh not_active IP Right Cessation
- 2002-05-14 BR BR0209652-8A patent/BR0209652A/pt not_active IP Right Cessation
- 2002-05-14 HU HU0304084A patent/HUP0304084A3/hu unknown
- 2002-05-14 AU AU2002314067A patent/AU2002314067B2/en not_active Ceased
- 2002-05-14 PL PL02366786A patent/PL366786A1/xx unknown
- 2002-05-15 PE PE2002000407A patent/PE20030042A1/es not_active Application Discontinuation
-
2003
- 2003-11-14 NO NO20035084A patent/NO20035084L/no not_active Application Discontinuation
- 2003-12-02 CO CO03105928A patent/CO5540347A2/es not_active Application Discontinuation
-
2004
- 2004-07-02 US US10/884,150 patent/US6992105B2/en not_active Expired - Fee Related
-
2005
- 2005-10-21 US US11/255,827 patent/US20060058242A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03010403A (es) | Derivados de dipeptido que tienen un grupo 2-tioacilo n-terminal como inhibidores de vasopeptidasa. | |
| AU2429297A (en) | Amidinohydrazones as protease inhibitors | |
| CA2400554A1 (en) | Pyrimidine-4-one derivatives as ldl-pla2 inhibitors | |
| AP2000001919A0 (en) | Inhibitors of caspases. | |
| AU1871301A (en) | Serine protease inhibitors | |
| WO2005012334A8 (ja) | 生体内非分解性ペプチド、アンジオテンシン変換酵素阻害剤、医薬及び機能性食品 | |
| IL126404A0 (en) | Pyrazinone thrombin inhibitors | |
| WO2002022576A3 (en) | 3-substituted indole carbohydrazides useful as cell proliferation and angiogenesis inhibitors | |
| DE59911670D1 (de) | Glutamin-Thiazolidide und -Pyrrolidide sowie ihre Verwendung als Dipeptidylpeptidase IV Inhibitoren | |
| AU2056197A (en) | M-amidino phenyl analogs as factor xa inhibitors | |
| UA74372C2 (uk) | Інгібітори серинових протеаз, фармацевтична композиція на їх основі | |
| AU2001274220A1 (en) | Serine protease inhibitors | |
| NO20004698D0 (no) | Quinoksalinoner som serin protease inhibitorer sÕ som faktor XA og trombin | |
| AU4269397A (en) | Method of cell surface activation and inhibition | |
| AU6571700A (en) | Enzymatic synthesis of deoxyribonucleosides | |
| PL353180A1 (en) | Glycine cleavage system inhibitors as potential antipsychotics | |
| DE60038350D1 (de) | Angiotensin-Converting-Enzyme-Hemmer | |
| AU2003217916A8 (en) | Stable formulations of angiotensin converting enzyme (ace) inhibitors | |
| MXPA03004879A (es) | Inhibidores de farnesiltransferasa. | |
| AU2001252419A1 (en) | Thrombin inhibitors | |
| TW200509911A (en) | Novel combination | |
| WO2001074348A8 (en) | Vasopeptidase inhibitors to treat isolated systolic hypertension | |
| ECSP034841A (es) | Derivados de dipeptido que tienen un grupo 2-tioacilo n-terminal como inhibidores de vasopeptidasa | |
| UA86417C2 (ru) | СОЕДИНЕНИЕ ИНГИБИТОРА Іf-КАНАЛОВ СИНУСНОГО УЗЛА И ИНГИБИТОРА АНГИОТЕНЗИНПРЕОБРАЗУЮЩЕГО ФЕРМЕНТА И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ | |
| SI1539815T1 (sl) | Kristalna struktura encima, ki pretvarja angiotenzin (ACE), in njegove uporabe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |